| Name | Title | Contact Details |
|---|---|---|
Justin Dean |
Chief Information Officer | Profile |
Justin Dean |
Chief Technology Officer and Chief Information Officer | Profile |
"Santa Cruz Nutritionals is the world's leading manufacturer of enhanced confectionery delivery systems for the functional food and supplement, or ""nutraceutical"" market. Using its unique food science expertise and proprietary processes the company has"
Managed Health Care Associates, Inc. (MHA) is not only the country`s largest alternate site GPO, but also has established itself as a leading health care services and technology company. This evolution reflects our commitment to stay abreast of changes in the alternate site health care market and invest in innovative solutions, technologies and services for our members including long-term care pharmacies, infusion pharmacies, specialty pharmacies, home medical equipment providers and assisted living and skilled nursing facilities.
Medelis is a Reno, NV-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Equiscript helps safety net providers better understand and grow their 340B pharmacy business. With a keen eye for detail, our skilled people assist our clients in the design and implementation of a home delivery pharmacy program intended to improve health outcomes by putting much-needed medicines into the hands of those patients in the communities we serve.
Theseus is a biopharmaceutical company focused on improving the lives of cancer patients through the discovery, development and commercialization of transformative targeted therapies. Theseus is developing next-generation tyrosine kinase inhibitors (TKIs): "pan-variant" targeted therapies that address all major drug resistance mutations. Theseus` lead product candidate, THE-630, is a pan-variant KIT inhibitor for the treatment of patients with advanced gastrointestinal stromal tumors (GIST), whose cancer has developed resistance to earlier lines of kinase inhibitor therapy. Theseus is also developing a fourth-generation, selective epidermal growth factor receptor (EGFR) inhibitor for C797S-mediated resistance to first- or later-line osimertinib treatment in patients with non-small cell lung cancer (NSCLC).